Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Apr 30;17(1):225.
doi: 10.1186/s13063-016-1350-0.

Dedicated call center (SOS-HAE) for hereditary angioedema attacks: study protocol for a randomised controlled trial

Nicolas Javaud  1 , Olivier Fain  2 , Isabelle Durand-Zaleski  3 , David Launay  4 , Laurence Bouillet  5 , Anne Gompel  6 , Alain Sobel  7 , Maguy Woimant  8 , Hasina Rabetrano  3 , Tomislav Petrovic  8 , Frédéric Lapostolle  8 , Isabelle Boccon-Gibod  5 , Paul-Georges Reuter  8 , Philippe Bertrand  8 , Brigitte Coppere  9 , Bernard Floccard  10 , Gisele Kanny  11 , Ludovic Martin  12 , Eric Vicaut  13 , Frédéric Adnet  8
Affiliations
Randomized Controlled Trial

Dedicated call center (SOS-HAE) for hereditary angioedema attacks: study protocol for a randomised controlled trial

Nicolas Javaud et al. Trials. .

Abstract

Background: Despite the availability of guidelines for the specific treatment of hereditary angioedema (HAE) attacks, HAE morbidity and mortality rates remain substantial. HAE attacks are a major medical issue requiring specific treatment as well as a considerable socio-economic burden. We report a protocol designed to test whether a dedicated call centre is more effective than usual practice in the management of patients experiencing an HAE attack.

Methods/design: This prospective, cluster-randomised, single-blind, parallel-group, multicentre trial evaluates the morbidity and consequent socio-economic costs of the management of patients experiencing an HAE attack by a dedicated call centre as compared to usual practice. The trial aims to recruit 200 patients. Patients in the intervention arm are provided with an SOS-HAE card with the call centre's freephone number that they can access in the case of an attack. The centre's mission is to provide recommended expert advice on early home treatment. The centre can route the call to a local emergency medical service with competency in HAE management or even arrange for the drugs needed for the specific treatment of an HAE attack to be sent to the emergency department of the local hospital. The primary outcome measure is the number of hospital admissions for an HAE attack. Each patient will be followed up every 2 months for 2 years. The study has been approved by the ethics committee (Comité de Protection des Personnes d'Ile de France 10; registration number: 2012-A00044-39; date of approval: 19 January 2012).

Discussion: The SOS-HAE protocol has been designed to address the handling of attacks experienced by patients with HAE in the home. The proposed trial will determine whether the setting up of a dedicated call centre is more effective than usual practice in terms of reducing morbidity as given by the numbers of hospital admissions. The results are also anticipated to have important implications in terms of socio-economic costs for both healthcare services and patients.

Trial registration: ClinicalTrials.gov NCT01679912 .

Keywords: Call centre; Emergency; Hereditary angioedema; Icatibant; Plasma-derived C1 inhibitor.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study design
Fig. 2
Fig. 2
Study flowchart
See this image and copyright information in PMC

References

    1. Longhurst H, Cicardi M. Hereditary angio-oedema. Lancet. 2012;379:474–81. doi: 10.1016/S0140-6736(11)60935-5. - DOI - PubMed
    1. Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69:602–16. doi: 10.1111/all.12380. - DOI - PubMed
    1. Zuraw BL, Bernstein JA, Lang DM, Craig T, Dreyfus D, Hsieh F, et al. A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. J Allergy Clin Immunol. 2013;131:1491–3. doi: 10.1016/j.jaci.2013.03.034. - DOI - PubMed
    1. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med. 2008;359:1027–36. doi: 10.1056/NEJMcp0803977. - DOI - PubMed
    1. Bork K, Staubach P, Eckardt AJ, Hardt J. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol. 2006;101:619–27. doi: 10.1111/j.1572-0241.2006.00492.x. - DOI - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources